NCT02988466 - Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

May 2, 2023

Study Completion Date

March 24, 2025

Conditions

Hematologic Malignancies

Interventions

BIOLOGICAL

Haplo HCT <55 years old

"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0"

BIOLOGICAL

Haplo HCT ≥55 years old

"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion"

DRUG

GVHD Prophylaxis

"* Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)"

BIOLOGICAL

Haplo HCT ≥55 and < 65 years old

"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells"

BIOLOGICAL

Haplo HCT ≥65 and ≤75 years old

"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)"

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors

lead

Masonic Cancer Center, University of Minnesota

OTHER